Skip to main content
CSBR logo

CSBR · Champions Oncology, Inc.

$5.26 -0.20 (-3.66%) At close · Jul 30
Market Cap
$73.08M
Shares
13.89M

Champions Oncology, Inc. Earnings Call Transcripts

Every quarterly earnings call for Champions Oncology, Inc. (CSBR) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY26 · Q4
2026-07-27
Champions Oncology, Inc. Q4 FY2026 Earnings Call
Revenue
$13.84M*
▲ 12% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY26 · Q3
2026-03-12
Champions Oncology, Inc. Q3 FY2026 Earnings Call
Positive tone Services revenue growth and operational performance Data business momentum and pipeline Investment in data platform and Discovery Therapeutics
Revenue
$16.56M
▼ 2.8% YoY
Diluted EPS
$-0.02
▼ 106.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2025-12-15
Champions Oncology, Inc. Q2 FY2026 Earnings Call
Revenue
$15.04M
▲ 11.5% YoY
Diluted EPS
$0.02
▼ 60% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2025-09-15
Champions Oncology, Inc. Q1 FY2026 Earnings Call
Revenue
$13.99M
▼ 0.5% YoY
Diluted EPS
$-0.03
▼ 133.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2025-07-23
Champions Oncology, Inc. Q4 FY2025 Earnings Call
Confident tone Data licensing platform Turnaround and return to profitability Core research services business
Revenue
$12.36M*
▼ 11.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-03-11
Champions Oncology, Inc. Q3 FY2025 Earnings Call
Revenue
$17.04M
▲ 41.8% YoY
Diluted EPS
$0.31
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2024-12-11
Champions Oncology, Inc. Q2 FY2025 Earnings Call
Revenue
$13.49M
▲ 16.6% YoY
Diluted EPS
$0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2024-09-11
Champions Oncology, Inc. Q1 FY2025 Earnings Call
Revenue
$14.06M
▲ 11.9% YoY
Diluted EPS
$0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-07-18
Champions Oncology, Inc. Q4 FY2024 Earnings Call
Revenue
$14.00M*
▲ 7.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-03-12
Champions Oncology, Inc. Q3 FY2024 Earnings Call
Revenue
$12.02M
▼ 5.9% YoY
Diluted EPS
$-0.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2023-12-12
Champions Oncology, Inc. Q2 FY2024 Earnings Call
Revenue
$11.57M
▼ 19% YoY
Diluted EPS
$-0.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2023-09-13
Champions Oncology, Inc. Q1 FY2024 Earnings Call
Revenue
$12.56M
▼ 8.6% YoY
Diluted EPS
$-0.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-07-24
Champions Oncology, Inc. Q4 FY2023 Earnings Call
Revenue
$13.07M*
▲ 1.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-03-15
Champions Oncology, Inc. Q3 FY2023 Earnings Call
Revenue
$12.77M
▼ 3.2% YoY
Diluted EPS
$-0.18
▼ 460% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2022-12-13
Champions Oncology, Inc. Q2 FY2023 Earnings Call
Revenue
$14.28M
▲ 21.2% YoY
Diluted EPS
$0.00
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2022-09-08
Champions Oncology, Inc. Q1 FY2023 Earnings Call
Revenue
$13.74M
▲ 22.1% YoY
Diluted EPS
$-0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-07-21
Champions Oncology, Inc. Q4 FY2022 Earnings Call
Revenue
$12.88M*
▲ 21.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-03-15
Champions Oncology, Inc. Q3 FY2022 Earnings Call
Revenue
$13.19M
▲ 22% YoY
Diluted EPS
$0.05
▼ 28.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2021-12-13
Champions Oncology, Inc. Q2 FY2022 Earnings Call
Revenue
$11.79M
▲ 16.5% YoY
Diluted EPS
$0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2021-09-13
Champions Oncology, Inc. Q1 FY2022 Earnings Call
Revenue
$11.25M
▲ 17.9% YoY
Diluted EPS
$-0.01
▼ 200% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-07-22
Champions Oncology, Inc. Q4 FY2021 Earnings Call
Revenue
$10.56M*
▲ 20.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-03-11
Champions Oncology, Inc. Q3 FY2021 Earnings Call
Revenue
$10.81M
▲ 20% YoY
Diluted EPS
$0.07
▲ 133.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2020-12-14
Champions Oncology, Inc. Q2 FY2021 Earnings Call
Revenue
$10.12M
▲ 32.7% YoY
Diluted EPS
$0.00
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2020-09-14
Champions Oncology, Inc. Q1 FY2021 Earnings Call
Revenue
$9.55M
▲ 41.7% YoY
Diluted EPS
$0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-07-27
Champions Oncology, Inc. Q4 FY2020 Earnings Call
Revenue
$8.75M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-03-12
Champions Oncology, Inc. Q3 FY2020 Earnings Call
Revenue
$9.01M
▲ 40.2% YoY
Diluted EPS
$0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2019-10-31
Champions Oncology, Inc. Q2 FY2020 Earnings Call
Revenue
$7.62M
▲ 13.9% YoY
Diluted EPS
$0.02
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–27 of 27 earnings calls
Key facts CIK 771856 CUSIP 15870P307 13F (30d) 4 filings 4 filers Visit website Investor relations